Trial Profile
The Guard1 Trial, an Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 for Subjects With Type 1 Gaucher Disease
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs AVR RD 02 (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Guard1; GuardOne
- Sponsors AVROBIO
- 21 Aug 2023 Status changed from recruiting to discontinued.
- 11 May 2023 According to an AVROBIO media release, safety and efficacy data presented at the 19th annual WORLDSymposium in February.
- 09 Feb 2023 According to an AVROBIO media release, preliminary safety, pharmacodynamic and clinical efficacy results will be presented at the 19th Annual WORLDSymposium 2023.